Computational Protein Design of Robust and Scalable Recombinant HRP and Poly-HRP Reagents
About This Grant
Project Summary: Horseradish peroxidase (HRP) is a critical reporter enzyme widely used in diagnostics, and research tools due to its ability to amplify signal in assays like ELISAs, Western blots, and immunohistochemistry. However, current HRP reagents are largely derived from horseradish root, which results in heterogeneous mixtures of isoenzymes with varying glycosylation patterns, activity, and stability. This variability compromises reproducibility, complicates regulatory compliance, and presents significant manufacturing challenges. Moreover, recombinant HRP production has been historically hindered by its complex structural requirements, including the incorporation of a heme cofactor, multiple disulfide bonds, calcium ions, and glycosylation, which are difficult to replicate in microbial hosts. As a result, efforts to create a consistent, recombinant HRP alternative have proven unsuccessful, with current solutions like poly-HRP showing significant limitations in batch-to-batch consistency which is critical in high sensitivity assays. This SBIR Phase I project aims to overcome these challenges by using state-of-the-art computational protein design to develop a novel recombinant HRP mimetic that exhibits high stability, catalytically active properties, and scalability. Our approach involves two primary innovations: the design of a stable, de novo HRP enzyme that can be expressed efficiently in microbial systems, and the development of a self-assembling HRP nanoparticle that enables precise control of enzyme stoichiometry and enhances performance consistency. The proposed HRP mimetic will not only ensure high-quality production of HRP reagents but also enable genetic fusions with other functional domains, opening the door to more consistent and reliable diagnostic development. Our team has developed promising preliminary data indicating a highly de-risked application that will have a big impact. Our preliminary data demonstrate the feasibility of using computational protein design to create a de novo HRP that is easy to manufacture, and with this grant, we intend to transform it into a high-impact product with broad applications.
Grant Summary
Computational Protein Design of Robust and Scalable Recombinant HRP and Poly-HRP Reagents is a NIGMS - National Institute of General Medical Sciences grant providing up to $331K for university, nonprofit, healthcare org. Applications are due 2027-07-31 (open). Check eligibility and apply with FindGrants.
Not quite the right fit?
Search 9,000+ open grants, or get matches ranked for your organization — free.
Focus Areas
Eligibility
How to Apply
Up to $331K
2027-07-31
- 1Confirm your organization is eligible for Computational Protein Design of Robust and Scalable Recombinant HRP and Poly-HRP Reagents from NIGMS - National Institute of General Medical Sciences, checking organization type, location, and any population or project requirements.
- 2Gather the required documents and information, including your organization details, project plan, and budget figures.
- 3Draft your application narrative and budget addressing the funder's priorities and review criteria. FindGrants can draft each section for you to review and edit.
- 4Review every section against the requirements checklist, then export a submission-ready application pack and submit it to NIGMS - National Institute of General Medical Sciences before the deadline.
Don't want to draft it yourself?
We'll draft the complete application against NIGMS - National Institute of General Medical Sciences's requirements, run a quality review, and email you a submission-ready PDF plus an editable Word doc within 5 business days. Most orders deliver in 24-48 hours. Flat $399, any grant size.
AI Requirement Analysis
Detailed requirements not yet analyzed
Have the NOFO? Paste it below for AI-powered requirement analysis.
Computational Protein Design of Robust and Scalable Recombinant HRP and Poly-HRP Reagents: Frequently Asked Questions
Who is eligible for the Computational Protein Design of Robust and Scalable Recombinant HRP and Poly-HRP Reagents?
Computational Protein Design of Robust and Scalable Recombinant HRP and Poly-HRP Reagents is offered by NIGMS - National Institute of General Medical Sciences and is generally open to university, nonprofit, healthcare org. It is open to organizations nationwide unless the funder specifies otherwise. Review the specific eligibility terms before applying, since funders set their own requirements around organization type, location, and the population or project being served.
How much funding does the Computational Protein Design of Robust and Scalable Recombinant HRP and Poly-HRP Reagents provide?
Computational Protein Design of Robust and Scalable Recombinant HRP and Poly-HRP Reagents provides up to $331K per award from NIGMS - National Institute of General Medical Sciences. Actual award sizes depend on the scope of your project, available program funds, and the number of applicants, so build a budget that reflects realistic, allowable costs rather than the maximum figure.
When is the Computational Protein Design of Robust and Scalable Recombinant HRP and Poly-HRP Reagents deadline?
Applications for Computational Protein Design of Robust and Scalable Recombinant HRP and Poly-HRP Reagents are due 2027-07-31 (open). Because deadlines can change, verify the date with the funder, NIGMS - National Institute of General Medical Sciences, and give yourself enough time to prepare a complete, competitive application before the close date.
How do you apply for the Computational Protein Design of Robust and Scalable Recombinant HRP and Poly-HRP Reagents?
To apply for Computational Protein Design of Robust and Scalable Recombinant HRP and Poly-HRP Reagents, confirm your eligibility, gather the required documents, and prepare a narrative and budget that address the funder's priorities. FindGrants guides you step by step and can draft each section, then exports a submission-ready application pack for this grant from NIGMS - National Institute of General Medical Sciences.